



## Arcturus Therapeutics to Host a Key Opinion Leader Call on Ornithine Transcarbamylase (OTC) Deficiency on December 11

December 3, 2018

SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, infectious, fibrotic, and respiratory diseases with significant unmet medical need, today announced that it will host a Key Opinion Leader (KOL) call for the investment community on current treatment options for ornithine transcarbamylase (OTC) deficiency on Tuesday, December 11 at 2:00 pm Eastern/11:00 am Pacific.

The call will feature a presentation by key opinion leader Annette Feigenbaum, MBChB, FRCP, DABMG, from the University of California - San Diego, who will discuss the disease pathogenesis, manifestation, natural history and current treatment options for ornithine transcarbamylase (OTC) deficiency. Dr. Feigenbaum will be available to answer questions at the conclusion of the call.

Dr. Pad Chivukula, Chief Scientific Officer of Arcturus Therapeutics, will also provide a brief overview of the company's ongoing LUNAR-OTC program, which utilizes the company's proprietary LUNAR® delivery platform to safely and effectively deliver OTC mRNA to liver cells, resulting in restoration of disease markers to normal levels.

Annette Feigenbaum, MBChB, FRCP, DABMG, is an associate physician at Rady Children's Hospital and University of California, San Diego, in the Department of Pediatrics and Biochemical Genetics. Her expertise is in the investigation, diagnosis, and management of inborn errors of metabolism, with a specific area of interest in urea cycle diseases. Dr. Feigenbaum qualified as a pediatrician in South Africa, followed by fellowships in clinical and biochemical genetics and research at the Hospital for Sick Children (SickKids) in Ontario, Canada, before being appointed as a staff physician in the Division of Clinical and Biochemical Genetics at SickKids. She continues as a part-time project investigator in the Department of Pediatrics and Research Institute at SickKids. She also serves as an associate professor at the University of Toronto. Dr. Feigenbaum has been site Principal Investigator for multiple clinical research studies in urea cycle diseases, PKU, and mitochondrial disease. She is certified in medical biochemical genetics by the American Board and the Canadian College of Medical Genetics.

### Conference Call and Live Webcast with Slides

Date: Tuesday, December 11  
Time: 2:00 pm EST/11:00 am PST  
Domestic: 1-888-224-1005  
International: 1-323-794-2551  
Conference ID: 5202083  
Webcast & <https://viaavid.webcasts.com>  
Replays: [/starthere.jsp?ei=1219310&tp\\_key=91d9e4a180](/starthere.jsp?ei=1219310&tp_key=91d9e4a180)  
To ask a  
Question: [Questions@LifeSciAdvisors.com](mailto:Questions@LifeSciAdvisors.com)

### About Arcturus Therapeutics Ltd.

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Ltd. (NASDAQ: ARCT) is an RNA medicines company with enabling technologies – UNA Oligomer chemistry and LUNAR® lipid-mediated delivery. Arcturus' diverse pipeline of RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis, and vaccines. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of RNA medicines including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA and gene editing therapeutics. Arcturus owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology including UNA Oligomers, which are covered by its extensive patent portfolio (140 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus' proprietary UNA technology can be used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. Arcturus' commitment to the development of novel RNA therapeutics has led to partnerships with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG and the Cystic Fibrosis Foundation. For more information, visit [www.Arcturusrx.com](http://www.Arcturusrx.com), the content of which is not incorporated herein by reference.

### Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, collaborations, future financial position, prospects, plans and objectives of management are forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements and you should not place undue reliance on such forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the company's LUNAR-OTC program and its potential use in treating Ornithine transcarbamylase (OTC) deficiency. Actual results and performance could differ materially from those projected in any forward-looking statements as a result of many factors, including without

limitation, an inability to develop and market product candidates. Such statements are based on management's current expectations and involve risks and uncertainties, including those discussed under the heading "Risk Factors" in Arcturus' Annual Report on Form 20-F for the fiscal year ended December 31, 2017, filed with the SEC on May 14, 2018 and in subsequent filings with, or submissions to, the SEC. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

**Contact**

Neda Safarzadeh  
Arcturus Therapeutics  
(858) 900-2682  
[IR@ArcturusRx.com](mailto:IR@ArcturusRx.com)

Arcturus Investor Contacts  
Michael Wood  
LifeSci Advisors LLC  
(646) 597-6983  
[mwood@lifesciadvisors.com](mailto:mwood@lifesciadvisors.com)



Source: Arcturus Therapeutics, Inc.